<DOC>
	<DOCNO>NCT03048253</DOCNO>
	<brief_summary>Recombinant human GM-CSF herpes simplex virus injection ( OrienX010 ) genetically engineer Chinese patient oral separation wild type 1 herpes simplex virus ( HSV ) carrier insert GM-CSF gene therapy drug.After gene recombination technology successively remove ICP34.5 , ICP47 insert deactivation ICP6 gene , site original ICP34.5 insert guide IE promoter hCMV human gm-csf gene.The drug tumor site local injection dose , one hand , soluble tumor characteristic herpes simplex virus , reconstruct HSV-1 virus carrier injection site specific `` soluble tumor '' kill tumor cell ; Viral vector express tumor site , hand , produce high concentration GM-CSF enhance antitumor immune function , play `` beside destruction effect '' , inhibition effect distant metastasis .</brief_summary>
	<brief_title>A Phase I-c Study Recombinant GM-CSF Herpes Simplex Virus TreatⅣ M1c</brief_title>
	<detailed_description>Subjects test drug within 8 x 107 pfu/ml tumor injection treatment , injection quantity accord tumor lesion size , injection amount shall exceed 10 ml time , injection frequency every 2 week , 4 time per cycle treatment , treatment 2 cycle . Completed end second cycle curative effect evaluation , researcher determine continue medicine bring benefit subject , continue offer benefit subject ' potential drug disease progression , small , tolerance toxicity participant withdraw consent .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>By histological and/or cytology diagnosis Ⅳ M1c malignant melanoma patient liver metastasis , lack effective method conventional failure conventional therapy recurrence General physical status score ( ECOG ) 02 point Lifetime expect 4 month Always antitumor treatment ( including/radiation therapy , immune therapy , target therapy , endocrine therapy , etc . ) end 4 week ( use nitroso urea class mitomycin chemotherapy drug withdrawal 6 week ) , always treat adverse reaction restore stability In group treat experimental drug within 4 week , intervene clinical research ( except epidemiological study ) In group four week receive treatment herpes simplex virus , acyclovir , ganciclovir , respectively.there galloway , vidarabine , etc In group four week much surgery Screening stage HSV 1 antibody IgG IgM negative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>